Combination therapy with GalNAc-siRNA drugs targeting both PCSK9 and APOC3 resulted in enhanced lipid lowering in mice

31 August 2024 (17:24 - 17:36)

Organised by:

Video

Abstract

Sign in to view the resources

Slides

About the speaker

Doctor Johannes Wikstrom

(Sweden)

4 More presentations in this session

Presentation thumbnail

Intraindividual variability in lipoprotein(a): the value of a repeat measure for reclassifying individuals at intermediate-risk

Doctor T. Harb (Baltimore, US)

Abstract Slides Video

Presentation thumbnail

Lipoprotein(a) metabolomic and proteomic features and atherosclerotic cardiovascular disease in young, asymptomatic adults

Associate Professor S. Goonewardena (Ann Arbor, US)

Abstract Slides Video

Presentation thumbnail

Reduction of triglyceride-rich lipoproteins with retatrutide in type 2 diabetes may be explained by concurrent reduction in ANGPTL3/8 levels

Doctor G. Ruotolo (Indianapolis, US)

Abstract Slides Video

Presentation thumbnail

Metabolomic profiling of the entire UK Biobank enables interpretation of familial hypercholesterolemia mutations and prediction of severe cardiovascular outcomes

Doctor J. Barrett (Helsinki, FI)

Abstract Slides Video

Access the full session

Session thumbnail

Lipids as cardiovascular risk factors and treatment options

The Event

Event poster

ESC Congress 2024

31 August 2024 17:24 CET

You may be interested in

Congress Presentation

RBD5044 - a novel anti-ApoC3 GalNAc-siRNA drug resulted in sustained and profound reduction of triglycerides in mice and Rhesus monkeys

Congress Presentation

RNA-based therapy in dyslipidaemia

Congress Presentation

Inhibition of liver ApoC3 by GalNAc-conjugated siRNA RBD5044: first-in-human trial to evaluate the safety, pharmacokinetics (PK), and pharmacodynamic (PD) effects on atherogenic lipid profiles in heal

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources